Vimarsana
Biggest News Aggregation in the World

Page 22 - Pfizer Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pfizer Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pfizer Ventures Today - Breaking & Trending Today

Funding News: Three Biopharmas Score a Combined $261 Million to Advance Pipelines - Vimarsana News

Funding News: Three Biopharmas Score a Combined $261 Million to Advance Pipelines

Published: May 18, 2021 By Alex Keown Three companies on three separate continents raised more than $250 million to advance their scientific visions of supporting and developing new therapies for life-threatening diseases.  Hummingbird Bioscience Raises $125 Million Singapore-based  raised $125 million in an oversubscribed Series C financing round. The funds will be used to support the development of the company’s two lead programs and advance its early-stage clinical research.  Hummingbird’s two lead assets are HMBD-001, a best-in-class HER3 antibody for NRG1-fusion and HER3-...

ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel ... - Vimarsana News

ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel ... AKAMPIONApril 12, 2021 GMT - Company forms international consortium with ProteoGenix SAS and Amsterdam UMC Schlieren (Zurich Area), Switzerland – April 12, 2021 – ImmunOs Therapeutics AG, a Swiss bio-technology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that is has received public funding from the European Union’s Eurostars-2 Progra...

Source: apnews.com
Palleon Pharmaceuticals Presents Data Suggesting Role of Hypersialylation in Metastatic Melanoma Pat - Vimarsana News

Palleon Pharmaceuticals Presents Data Suggesting Role of Hypersialylation in Metastatic Melanoma Pat

Search jobs 09-Apr-2021 Palleon Pharmaceuticals Presents Data Suggesting Role of Hypersialylation in Metastatic Melanoma Patients’ Resistance to PD1 Inhibitors WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, today announced the presentation of data supporting the role of hypersialylation in the immune escape of metastatic melanoma at the AACR Annual Meeting held virtually April 10-15, 2021. The research, conducted in collaborat...

Arix Bioscience PLC: Artios announces collaboration with Novartis to create next generation DDR cancer therapies - Vimarsana News

Arix Bioscience PLC: Artios announces collaboration with Novartis to create next generation DDR cancer therapies

Arix Bioscience PLC: Artios announces collaboration with Novartis to create next generation DDR cancer therapies DJ Artios announces collaboration with Novartis to create next generation DDR cancer therapies Arix Bioscience PLC (ARIX) Artios announces collaboration with Novartis to create next generation DDR cancer therapies 07-Apr-2021 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. =-------------------------------------------------------------------------------------------------...

Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies - Vimarsana News

Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies Artios Pharma, Inc.April 7, 2021 GMT Novartis to leverage Artios’ discovery platform to identify DDR targets for use with Novartis’ proprietary radioligand therapies. Artios to receive US$20 million up-front payment in addition to near term research funding to support the collaboration. Artios eligible to receive up to $1.3 billion in discovery, development, regulatory and sales-based milestones in...

Source: apnews.com